Raymond James & Associates Gain Therapeutics, Inc. Transaction History

Raymond James & Associates

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	BUY	$3.21 - $5.04 $758,301 - $1.19 Million	236,231 Added 993.07%	260,019 $980,000
Q4 2023 Jan 16, 2024	SELL	$2.07 - $3.4 $20,724 - $34,040	-10,012 Reduced 29.62%	23,788 $77,000
Q3 2023 Oct 24, 2023	BUY	$3.19 - $4.68 $1,276 - $1,872	400 Added 1.2%	33,800 $110,000
Q2 2023 Jul 25, 2023	BUY	$4.36 - $5.5 $58,424 - $73,700	13,400 Added 67.0%	33,400 $149,000
Q1 2023 Apr 14, 2023	SELL	$3.18 - $5.16 $12,720 - $20,640	-4,000 Reduced 16.67%	20,000 $96,000
Q3 2022 Oct 25, 2022	BUY	$3.17 - $4.21 $76,080 - $101,040	24,000 New	24,000 $78,000

2.39M

10K

Ticker GANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,883,400
Market Cap $20.4M
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.